Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06575933 | A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04384146 | Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04312308 | A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients | completed | — | 100 | Yonsei UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04809103 | Intratumoral Cisplatin for Resectable NSCLC | completed | Phase 1 | 6 | University of VermontOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04184921 | Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients | completed | Phase 2 | 216 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05429320 | A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT06675695 | Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases | completed | — | 4,864 | Brigham and Women's HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04648033 | Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC(ARCADIAN) | completed | Phase 1 | 21 | University of OxfordOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01897480 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations(Balise) | completed | Phase 2 | 168 | Eli Lilly and CompanyINDUSTRY | 9 | Jan 26, 2026 | clinicaltrials |
| NCT03003468 | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | completed | Phase 1 / Phase 2 | 35 | Lawrence Feldman, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03285321 | Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 105 | Greg Durm, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 92 | ExelixisINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04452877 | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | completed | Phase 2 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06629714 | Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients | completed | — | 196 | Anhui Medical UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02442349 | Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific(AURA17) | completed | Phase 2 | 171 | AstraZenecaINDUSTRY | 3 | Jan 9, 2026 | clinicaltrials |
| NCT07141563 | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC | completed | — | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | completed | Phase 2 | 47 | Revolution Medicines, Inc.INDUSTRY | 10 | Jan 6, 2026 | clinicaltrials |
| NCT06029127 | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | BeiGeneINDUSTRY | 2 | Jan 5, 2026 | clinicaltrials |
| NCT02473133 | Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC(RTEP7) | completed | Phase 2 | 158 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02821936 | Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer(PARAPET) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03832348 | Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment(iTEP1) | completed | N/A | 40 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 16 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04045496 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 40 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03810807 | Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04589013 | Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer(PRINCE) | completed | — | 106 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT00213798 | Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients | completed | N/A | 200 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT05465343 | Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) | completed | Phase 2 | 24 | Peking Union Medical CollegeOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04965090 | A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT07267247 | Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer | completed | — | 100 | Taichung Veterans General HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03926260 | Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA(ELUCID) | completed | N/A | 100 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2026source: clinicaltrials